Wolfe Research Initiates Coverage On BeOne Medicines with Outperform Rating, Announces Price Target of $340

Benzinga Newsdesk www.benzinga.com Positive 64.8%

Neg 0% Neu 0% Pos 64.8%

Wolfe Research analyst Kalpit Patel initiates coverage on BeOne Medicines (NASDAQ:ONC) with a Outperform rating and announces Price Target of $340.